Network-based integration of multi-omics data for prioritizing cancer genes

Motivation: Several molecular events are known to be cancer‐related, including genomic aberrations, hypermethylation of gene promoter regions and differential expression of microRNAs. These aberration events are very heterogeneous across tumors and it is poorly understood how they affect the molecular makeup of the cell, including the transcriptome and proteome. Protein interaction networks can help decode the functional relationship between aberration events and changes in gene and protein expression. Results: We developed NetICS (Network‐based Integration of Multi‐omics Data), a new graph diffusion‐based method for prioritizing cancer genes by integrating diverse molecular data types on a directed functional interaction network. NetICS prioritizes genes by their mediator effect, defined as the proximity of the gene to upstream aberration events and to downstream differentially expressed genes and proteins in an interaction network. Genes are prioritized for individual samples separately and integrated using a robust rank aggregation technique. NetICS provides a comprehensive computational framework that can aid in explaining the heterogeneity of aberration events by their functional convergence to common differentially expressed genes and proteins. We demonstrate NetICS’ competitive performance in predicting known cancer genes and in generating robust gene lists using TCGA data from five cancer types. Availability and implementation: NetICS is available at https://github.com/cbg‐ethz/netics. Supplementary information: Supplementary data are available at Bioinformatics online.

[1]  M. Mann,et al.  Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status , 2016, Nature Communications.

[2]  D. Cleveland,et al.  Chromoanagenesis and cancer: mechanisms and consequences of localized, complex chromosomal rearrangements , 2012, Nature Medicine.

[3]  Wei Gu,et al.  Synergistic activation of transcription by CBP and p53 , 1997, Nature.

[4]  Niko Beerenwinkel,et al.  Computational approaches for the identification of cancer genes and pathways , 2016, Wiley interdisciplinary reviews. Systems biology and medicine.

[5]  Xiaoping Zhou,et al.  Nerve growth factor receptor negates the tumor suppressor p53 as a feedback regulator , 2016, eLife.

[6]  Richard L. Halpert,et al.  Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer , 2016, Clinical Cancer Research.

[7]  Eric O'Neill,et al.  PI3K/Akt-mediated regulation of p53 in cancer. , 2014, Biochemical Society transactions.

[8]  Carlos Caldas,et al.  Mutations truncating the EP300 acetylase in human cancers , 2000, Nature Genetics.

[9]  R. Sears,et al.  Endogenous c-Myc is essential for p53-induced apoptosis in response to DNA damage in vivo , 2014, Cell Death and Differentiation.

[10]  Hsien-Da Huang,et al.  miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database , 2015, Nucleic Acids Res..

[11]  Norbert Senninger,et al.  EP300—A miRNA‐regulated metastasis suppressor gene in ductal adenocarcinomas of the pancreas , 2010, International journal of cancer.

[12]  I. Varela,et al.  PLCG1 mutations in cutaneous T-cell lymphomas. , 2014, Blood.

[13]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[14]  B. Thimmapaya,et al.  c-Myc-induced Aberrant DNA Synthesis and Activation of DNA Damage Response in p300 Knockdown Cells* , 2009, Journal of Biological Chemistry.

[15]  Geoffrey J. Barton,et al.  Probabilistic prediction and ranking of human protein-protein interactions , 2007, BMC Bioinformatics.

[16]  Jae Hoon Kim,et al.  MicroRNA Expression Profiles in Serous Ovarian Carcinoma , 2008, Clinical Cancer Research.

[17]  Spyro Mousses,et al.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.

[18]  Kenneth H. Buetow,et al.  PID: the Pathway Interaction Database , 2008, Nucleic Acids Res..

[19]  L. Stein,et al.  A human functional protein interaction network and its application to cancer data analysis , 2010, Genome Biology.

[20]  N. McGranahan,et al.  The causes and consequences of genetic heterogeneity in cancer evolution , 2013, Nature.

[21]  A. Bashashati,et al.  DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer , 2012, Genome Biology.

[22]  M. Stratton,et al.  Recurrent PTPRB and PLCG1 mutations in angiosarcoma , 2014, Nature Genetics.

[23]  Robin Kirschbaum,et al.  Questions and answers , 2009, Diabetes, obesity & metabolism.

[24]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[25]  John D. Minna,et al.  XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer , 2016, Nature.

[26]  Wei Li,et al.  MiR-429 is an independent prognostic factor in colorectal cancer and exerts its anti-apoptotic function by targeting SOX2. , 2013, Cancer letters.

[27]  Dirk,et al.  XPO 1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer , 2016 .

[28]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[29]  Edwin Sandanaraj,et al.  Attenuated adenosine-to-inosine editing of microRNA-376a* promotes invasiveness of glioblastoma cells. , 2012, The Journal of clinical investigation.

[30]  Michael L. Gatza,et al.  An integrated genomics approach identifies drivers of proliferation in luminal subtype human breast cancer , 2014, Nature Genetics.

[31]  Minoru Kanehisa,et al.  KEGG: new perspectives on genomes, pathways, diseases and drugs , 2016, Nucleic Acids Res..

[32]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[33]  Luciano Milanesi,et al.  Methods for the integration of multi-omics data: mathematical aspects , 2016, BMC Bioinformatics.

[34]  A. Børresen-Dale,et al.  Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.

[35]  Illés J. Farkas,et al.  SignaLink 2 – a signaling pathway resource with multi-layered regulatory networks , 2013, BMC Systems Biology.

[36]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[37]  David Haussler,et al.  Discovering causal pathways linking genomic events to transcriptional states using Tied Diffusion Through Interacting Events (TieDIE) , 2013, Bioinform..

[38]  F. Slack,et al.  MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications , 2013, Genome Medicine.

[39]  Anushya Muruganujan,et al.  PANTHER version 11: expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements , 2016, Nucleic Acids Res..

[40]  Benjamin J. Raphael,et al.  Pan-Cancer Network Analysis Identifies Combinations of Rare Somatic Mutations across Pathways and Protein Complexes , 2014, Nature Genetics.

[41]  S. Nishizuka,et al.  Reverse-phase protein lysate microarrays for cell signaling analysis , 2008, Nature Protocols.

[42]  Y. Benjamini,et al.  Resampling-based false discovery rate controlling multiple test procedures for correlated test statistics , 1999 .

[43]  Lincoln Stein,et al.  Reactome: a database of reactions, pathways and biological processes , 2010, Nucleic Acids Res..

[44]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[45]  N. Carter,et al.  Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development , 2011, Cell.

[46]  O. Yamanoshita,et al.  GNG2 inhibits invasion of human malignant melanoma cells with decreased FAK activity. , 2014, American journal of cancer research.

[47]  Livia Perfetto,et al.  SIGNOR: a database of causal relationships between biological entities , 2015, Nucleic Acids Res..